产品
编 号：F195559
分子式：C23H21F3N6S
分子量：470.51
分子式：C23H21F3N6S
分子量：470.51
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1628316-74-4
产品详情
生物活性：
MI-136 is an inhibitor of the menin-MLL protein-protein interaction (PPI), with an IC50 of 31 nM and a Kd of 23.6 nM. MI-136 shows to block AR signaling and has the potential for the study in castration-resistant tumors.
体内研究：
MI-136 exhibits T1/2 of 3.1 h after po administration.MI-136 (40 mg/kg, ip) leads to a significant decrease in the growth of castration-resistant VCaP tumors.Animal Model:VCaP xenografts.
Dosage:40 mg/kg.
Administration:Intraperitoneal injection, 5 days a week.
Result:Led to a significant decrease in the growth of castration-resistant VCaP tumors compared to vehicle controls.
体外研究：
MI-136 (0-20) exhibits IC50values of 5.59 μM, 7.15 μM, 5.37 μM and 19.76 μM in LNCaP, VCaP, 22rv1 and PNT2 cells.
MI-136 is an inhibitor of the menin-MLL protein-protein interaction (PPI), with an IC50 of 31 nM and a Kd of 23.6 nM. MI-136 shows to block AR signaling and has the potential for the study in castration-resistant tumors.
体内研究：
MI-136 exhibits T1/2 of 3.1 h after po administration.MI-136 (40 mg/kg, ip) leads to a significant decrease in the growth of castration-resistant VCaP tumors.Animal Model:VCaP xenografts.
Dosage:40 mg/kg.
Administration:Intraperitoneal injection, 5 days a week.
Result:Led to a significant decrease in the growth of castration-resistant VCaP tumors compared to vehicle controls.
体外研究：
MI-136 (0-20) exhibits IC50values of 5.59 μM, 7.15 μM, 5.37 μM and 19.76 μM in LNCaP, VCaP, 22rv1 and PNT2 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备